Global Patient-Derived Xenograft/PDX Model Market Research Report to 2027 - Featuring Champions Oncology, Envigo, Genesis Biotechnology and SR Among Others - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Patient-Derived Xenograft/PDX Model Market Research Report by Type (Mice Models and Rat Models), End User, Tumor Type, Application, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.

The Global Patient-Derived Xenograft/PDX Model Market size was estimated at USD 171.22 million in 2021, USD 194.97 million in 2022, and is projected to grow at a CAGR 14.12% to reach USD 378.32 million by 2027.

Competitive Strategic Window:

The Competitive Strategic Window analyzes the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Patient-Derived Xenograft/PDX Model Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Patient-Derived Xenograft/PDX Model Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Patient-Derived Xenograft/PDX Model Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Patient-Derived Xenograft/PDX Model Market?

4. What is the competitive strategic window for opportunities in the Global Patient-Derived Xenograft/PDX Model Market?

5. What are the technology trends and regulatory frameworks in the Global Patient-Derived Xenograft/PDX Model Market?

6. What is the market share of the leading vendors in the Global Patient-Derived Xenograft/PDX Model Market?

7. What modes and strategic moves are considered suitable for entering the Global Patient-Derived Xenograft/PDX Model Market?

Market Dynamics

Drivers

• Growing Demand for Personalized Medicine
• Oncology and Preclinical Development
• Government Programs Funding and Services for Applicants in the Preparation of Their Preclinical Programs and Documentation

Restraints

• High Cost of Personalized Pdx Model

Opportunities

• Rising Demand for Humanized Pdx Model
• Growth in Pharma R&D

Challenges

• Stringent Guidelines Regarding the Ethical Use of Animals in Cancer Research

Companies Mentioned

• Abnova Corporation
• Champions Oncology, Inc.
• Charles River Laboratories
• Envigo
• EPO Berlin-Buch GmbH
• Explora BioLabs
• Genesis Biotechnology Group
• Hera BioLabs
• Oncodesign
• Pharmatest Services
• SR Corporation
• THE JACKSON LABORATORY
• Urosphere
• WuXi AppTec
• Xentech

For more information about this report visit https://www.researchandmarkets.com/r/cpodbp

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900